AI Detects Major Heart Disease From a Single Ultrasound View

NEW YORK, NY – January 26, 2026 – A groundbreaking study published today provides powerful clinical evidence that artificial intelligence can accurately detect major heart diseases from a single, brief ultrasound clip, a development poised to revolutionize cardiac screening and make specialist-level diagnostics accessible at the point of care.

The research, published in the peer-reviewed journal Frontiers in Digital Health, validates an AI model developed by AISAP, a leader in AI-powered diagnostics. The findings demonstrate that complex cardiac conditions, including heart failure and significant valvular disease, can be identified with high accuracy using handheld ultrasound devices, even when operated by non-specialists. This breakthrough signals a major step toward democratizing cardiac care and enabling earlier, life-saving interventions.

The Science Behind the Breakthrough

The study, titled “Artificial intelligence assessment of valvular disease and ventricular function by a single echocardiography view,” is notable for both its scale and its outcomes. Researchers trained the deep learning algorithm by performing a retrospective analysis of more than 120,000 echocardiographic studies. The AI model was then validated against a prospective cohort of patients in a real-world clinical setting.

Its performance was exceptional. The AI achieved an Area Under the Curve (AUC)—a key measure of diagnostic accuracy—of up to 0.97 for detecting reduced ejection fraction (a hallmark of heart failure) and 0.95 for identifying right ventricular dysfunction. Crucially, the model accomplished this by analyzing only standard 2D grayscale video clips, bypassing the need for more complex and operator-dependent techniques like color flow doppler.

“The findings of this study represent a significant shift in how we approach cardiac screening,” stated Dr. Lior Fisher, the study's lead author and a physician at the Leviev Cardiovascular Institute at Sheba Medical Center. “By proving that a single-view acquisition can yield such high diagnostic accuracy for major pathologies like heart failure and valvular regurgitation, we are effectively removing the technical barriers to cardiac imaging. This allows a much broader range of clinicians to identify potentially life-threatening conditions at the point of care, long before a patient reaches the echo lab.”

Dismantling Diagnostic Barriers

Traditionally, a comprehensive echocardiogram is a resource-intensive procedure. It requires a highly trained sonographer to capture images from multiple specific angles, followed by expert interpretation from a cardiologist. This multi-step workflow can introduce significant delays, with patients sometimes waiting days or even weeks for a definitive diagnosis.

AISAP's technology aims to dismantle these bottlenecks. The study confirms that even clinicians who are not cardiologists can use affordable, handheld ultrasound devices to capture the necessary data for the AI to perform its analysis. This capability could empower frontline medical staff in emergency rooms, internal medicine wards, and remote rural clinics to conduct immediate, specialist-grade triage directly at the patient's bedside.

The implications are particularly profound for aging populations. Valvular heart disease is most prevalent in individuals over 65, a demographic where early detection is critical to preventing severe outcomes and improving quality of life. By simplifying the screening process, the technology promises to catch these conditions far earlier than current standards of care typically allow, enabling timely intervention and management.

Innovation in a Competitive AI Landscape

The field of AI-driven cardiac diagnostics is burgeoning with innovation, as companies race to make imaging faster, more accurate, and more accessible. Competitors like GE HealthCare's Caption Health have pioneered AI-guided acquisition to help non-specialists capture quality images, while firms such as Ultromics offer automated analysis of full echocardiogram studies to improve efficiency.

AISAP's approach, as validated in the new study, carves out a distinct niche by demonstrating that clinically meaningful, high-level triage can be performed from minimal data input—a single view. This focus on data efficiency could further lower the barrier to entry, making rapid screening feasible in even the most time-constrained clinical environments. The broader industry trend is a clear move toward integrating these AI tools with Point-of-Care Ultrasound (POCUS) devices, effectively decentralizing diagnostic power from specialized labs to the patient's bedside.

The robustness of the AI model is built on an extensive and sophisticated training regimen. To ensure the algorithm performs reliably on images of varying quality—a common challenge with POCUS—AISAP employed advanced techniques like data augmentation and domain-adversarial training. This prepares the AI to handle the real-world variability of scans performed by different users on different devices, a crucial step for widespread and equitable clinical adoption.

From Research to Real-World Impact

While this single-view research informs the company's future innovation pipeline, AISAP’s FDA-cleared POCAD™ (Point-of-Care Assisted Diagnosis) platform is already deployed in clinical settings. The system is designed to facilitate a rapid, five-minute scan and deliver AI-assisted measurements and diagnostic support, streamlining the entire workflow from image capture to report.

The technology's credibility is bolstered by validation studies at world-renowned institutions, including Mass General Brigham, the Mayo Clinic, and Thomas Jefferson University Hospital. These collaborations have demonstrated that the platform not only works in a lab but enhances clinician accuracy in real-world practice. Research at Mass General Brigham, for instance, found that AISAP’s AI measurements often aligned more closely with the consensus of three expert cardiologists than any single expert's individual reading, highlighting its potential to reduce diagnostic variability and boost clinical confidence.

“This validation reflects our commitment to continue advancing what's possible with AI in healthcare,” said Adiel Am-Shalom, CEO and Co-Founder of AISAP. “By proving that AI can rapidly extract clinically meaningful signatures from minimal ultrasound data, this study confirms that our POCAD™ platform isn't just a tool for clinicians, it is a potential lifeline for patients.”

The economic and public health implications are substantial. Early detection of conditions like aortic stenosis can avert significant downstream costs associated with disease progression and, more importantly, improve patient outcomes. By making advanced diagnostics more accessible, this technology directly addresses healthcare disparities, offering a pathway to bring specialist-level care to underserved communities, from major U.S. health systems to remote rural clinics around the globe.